Literature DB >> 35106093

Assessment of the control measures of category A diseases of the Animal Health Law: Infection with rinderpest virus (Rinderpest).

Søren Saxmose Nielsen, Julio Alvarez, Dominique Joseph Bicout, Paolo Calistri, Elisabetta Canali, Julian Ashley Drewe, Bruno Garin-Bastuji, José Luis Gonzales Rojas, Christian Gortázar, Mette Herskin, Virginie Michel, Miguel Ángel Miranda Chueca, Barbara Padalino, Paolo Pasquali, Hans Spoolder, Karl Ståhl, Antonio Velarde, Arvo Viltrop, Christoph Winckler, Kris De Clercq, Simon Gubbins, Genevieve Libeau, Andrea Gervelmeyer, Helen Clare Roberts.   

Abstract

EFSA received a mandate from the European Commission to assess the effectiveness of control measures against diseases included in the Category A list according to Regulation (EU) 2016/429 on transmissible animal diseases ('Animal Health Law'). This opinion belongs to a series of opinions where these control measures are assessed, with this opinion covering the assessment of control measures for rinderpest (RP), the only animal disease to have been globally eradicated. In this opinion, the AHAW Panel reviewed the effectiveness of: (i) clinical and laboratory sampling procedures, (ii) monitoring period and (iii) the minimum radius of the protection and surveillance zone, and the minimum length of time the measures should be applied in these zones. The general methodology used for this series of opinions has been published elsewhere. The transmission kernels used for the assessment of the minimum radius of the protection and surveillance zones are shown. Several scenarios for which control measures had to be assessed were agreed prior to the assessment. Considering that RP has been eradicated globally, a re-emergence that is not stopped in its early phases could have a devastating impact on animal health and the economy. The panel concludes that no suitable strategies are available to entirely mitigate the risk associated with granting derogations from killing of animals in an affected establishment or for animal movements. Therefore, the panel recommends to not grant any derogations. The monitoring period of 21 days was assessed as effective, except for the hypothetical first re-emergence of RP, when lack of awareness and diagnostic capability may extend the time to detection. It was concluded that the protection and the surveillance zones would contain 90% and > 99%, respectively, of the infections from an affected establishment. Enlarging the protection zone to 4 km would contain the disease spread with 95% probability.
© 2022 Wiley‐VCH Verlag GmbH & Co. KgaA on behalf of the European Food Safety Authority.

Entities:  

Keywords:  RP; disease control measures; monitoring period; protection zone; rinderpest; sampling procedures; surveillance zone

Year:  2022        PMID: 35106093      PMCID: PMC8787597          DOI: 10.2903/j.efsa.2022.7071

Source DB:  PubMed          Journal:  EFSA J        ISSN: 1831-4732


  27 in total

1.  Trial of a capripoxvirus-rinderpest recombinant vaccine in African cattle.

Authors:  C K Ngichabe; H M Wamwayi; T Barrett; E K Ndungu; D N Black; C J Bostock
Journal:  Epidemiol Infect       Date:  1997-02       Impact factor: 2.451

2.  Response of white-tailed deer to infection with peste des petits ruminants virus.

Authors:  F M Hamdy; A H Dardiri
Journal:  J Wildl Dis       Date:  1976-10       Impact factor: 1.535

3.  A microneutralization test for the detection of rinderpest virus antibodies.

Authors:  W P Taylor; L W Rowe
Journal:  Rev Elev Med Vet Pays Trop       Date:  1984

4.  A model of lineage-1 and lineage-2 rinderpest virus transmission in pastoral areas of East Africa.

Authors:  J C Mariner; J McDermott; J A P Heesterbeek; A Catley; P Roeder
Journal:  Prev Vet Med       Date:  2005-03-29       Impact factor: 2.670

5.  Vaccination of cattle with attenuated rinderpest virus stimulates CD4(+) T cell responses with broad viral antigen specificity.

Authors:  Brett T Lund; Ashok Tiwari; Sareen Galbraith; Michael D Baron; W Ivan Morrison; Tom Barrett
Journal:  J Gen Virol       Date:  2000-09       Impact factor: 3.891

6.  Specific detection of Rinderpest virus by real-time reverse transcription-PCR in preclinical and clinical samples from experimentally infected cattle.

Authors:  C Carrillo; M Prarat; A Vagnozzi; J D Calahan; G Smoliga; W M Nelson; L L Rodriguez
Journal:  J Clin Microbiol       Date:  2010-09-15       Impact factor: 5.948

7.  Rinderpest virus (RPV) ISCOM vaccine induces protection in cattle against virulent RPV challenge.

Authors:  H Kamata; K Ohishi; E Hulskotte; A D Osterhaus; K Inui; M S Shaila; K Yamanouchi; T Barrett
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

8.  Immunological responses of mice and cattle to baculovirus-expressed F and H proteins of rinderpest virus: lack of protection in the presence of neutralizing antibody.

Authors:  M Bassiri; S Ahmad; L Giavedoni; L Jones; J T Saliki; C Mebus; T Yilma
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

9.  Hematologic Studies of Rinderpest-Infected Swine.

Authors:  W P Heuschele; T L Barber
Journal:  Can J Comp Med Vet Sci       Date:  1963-03

10.  Decision Support for Mitigation of Livestock Disease: Rinderpest as a Case Study.

Authors:  Judith R Mourant; Paul W Fenimore; Carrie A Manore; Benjamin H McMahon
Journal:  Front Vet Sci       Date:  2018-09-03
View more
  1 in total

1.  Assessment of the control measures of the Category A diseases of the Animal Health Law: prohibitions in restricted zones and risk-mitigating treatments for products of animal origin and other materials.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar Schmidt; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Barbara Padalino; Paolo Pasquali; Karl Stahl; Antonio Velarde Calvo; Arvo Viltrop; Christoph Winckler; Kris De Clercq; Ylva Sjunnesson; Andrea Gervelmeyer; Helen Clare Roberts
Journal:  EFSA J       Date:  2022-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.